OSL oncosil medical ltd

0.86%

$1.16

EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma... Hong-Kong, page-5

First 5 Last

whytee

17,584 Posts.

2536

08/12/21

14:18

Post #: 58160969

Originally posted by JPGuru ↑

This one surprised me but it seems the device is registered in hong kong and now they are working on trial which is positive step. As per my previous post about Hong Kong Approval the device registration last for 5 years and this trail below if successful will give validation to safety and usefulness of the device in down staging tumor.

Good luck all holders... !

Abstract from trial submission below.
Sponsor:
Chinese University of Hong Kong
Information provided by (Responsible Party):
Anthony Teoh, Chinese University of Hong Kong

Study Description

Go to
Brief Summary:
The outcomes of concurrent EUS-guided intra-tumour injection of P-32 microparticles (OncoSil; OncoSil Medical, Australia) with chemotherapy in locally advanced pancreatic carcinoma in the local population is uncertain.
The aim of the current study is to assess efficacy and safety of the intervention in the local population. We hypothesis that the intervention is safe and useful for tumour downstaging.

Condition or disease Intervention/treatment Phase

1 Pancreatic CancerEndoscopic Ultrasound Device: EUS-guided oncosil injection Phase 2Phase 3

mce-anchor
mce-anchorDetailed Description:
This would be a cohort study including patients with locally advanced pancreatic cancer medically fit to receive chemotherapy. Eligible patients would receive gemcitabine (GNP; 28- day cycles). P-32 microparticles (OncoSil; OncoSil Medical) implantation will be planned at weeks 4-5. P-32 activity will be calculated from patients' tumor volume (TV) to deliver 100 Gy absorbed dose, with implantation assessment by EUS and Bremsstrahlung SPECT/CT imaging. The primary endpoint was safety and tolerability, graded using CTCAE v4.0. Response will be assessed using RECIST 1.1 with 8-weekly CT scans and FDG-PET scans at baseline and week 12. The outcome parameters include adverse events, response of the tumour, local progression free survival and overall survival (OS).
Study Design

Go to

Column 1 Column 2

0 Study Type : Interventional (Clinical Trial)

1 Estimated Enrollment : 20 participants

2 Allocation: N/A

3 Intervention Model: Single Group Assignment

4 Intervention Model Description: OncoSil™ is comprised of OncoSil Phosphorous-32 Microparticles (hereafter Microparticles) and OncoSil Diluent (hereafter Diluent). OncoSil™ is an active implantable (radiological) medical device intended for use in brachytherapy, where cancer is treated by the insertion of radioactive implants directly into the cancerous tissue. OncoSil™ has been designed to be injected directly into, and to deliver an average absorbed dose of 100 Gy to the target treatment tumour. In therapeutic use 98% of the radiation is delivered within 81 days.

5 Masking: None (Open Label)

6 Primary Purpose: Treatment

7 Official Title: Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.

8 Actual Study Start Date : November 1, 2021

9 Estimated Primary Completion Date : October 31, 2024

10 Estimated Study Completion Date : October 31, 2024

Expand

Good find, and there may be others in the works.
However the results might not be available until maybe Mar 2025 so plenty of time?

OSL Price at posting: 4.2¢ Sentiment: None Disclosure: Not Held

Upvote

0 Great analysis

Top Stories

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Most investors will get this earnings season wrong. Will you?

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

ASE

Astute delivers high-grade lithium hits at Red Mountain

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.16		Change -0.010(0.86%)		Mkt cap ! $21.74M

Open	High	Low	Value	Volume
$1.17	$1.17	$1.14	$80.47K	69.48K

Buyers (Bids)

No.	Vol.	Price($)
1	2150	$1.16

Sellers (Offers)

Price($)	Vol.	No.
$1.17	7380	1

View Market Depth

No.	Vol.	Price($)
1	8695	1.150
2	10757	1.140
1	5000	1.135
1	2000	1.130
2	5700	1.115

Price($)	Vol.	No.
1.170	7380	1
1.180	5000	1
1.190	25000	1
1.205	1563	1
1.210	5000	2

Last trade - 16.10pm 25/07/2025 (20 minute delay)

OSL (ASX) Chart

EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma... Hong-Kong, page-5

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Most investors will get this earnings season wrong. Will you?

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Astute delivers high-grade lithium hits at Red Mountain

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	Column 1	Column 2
0	Study Type :	Interventional (Clinical Trial)
1	Estimated Enrollment :	20 participants
2	Allocation:	N/A
3	Intervention Model:	Single Group Assignment
4	Intervention Model Description:	OncoSil™ is comprised of OncoSil Phosphorous-32 Microparticles (hereafter Microparticles) and OncoSil Diluent (hereafter Diluent). OncoSil™ is an active implantable (radiological) medical device intended for use in brachytherapy, where cancer is treated by the insertion of radioactive implants directly into the cancerous tissue. OncoSil™ has been designed to be injected directly into, and to deliver an average absorbed dose of 100 Gy to the target treatment tumour. In therapeutic use 98% of the radiation is delivered within 81 days.
5	Masking:	None (Open Label)
6	Primary Purpose:	Treatment
7	Official Title:	Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.
8	Actual Study Start Date :	November 1, 2021
9	Estimated Primary Completion Date :	October 31, 2024
10	Estimated Study Completion Date :	October 31, 2024

EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma... Hong-Kong, page-5

Top Stories

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Most investors will get this earnings season wrong. Will you?

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Astute delivers high-grade lithium hits at Red Mountain

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News